Ranger Biotechnologies A/S: Financial statements 2014
CVR: 32280404
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
Ranger Biotechnologies A/S (CVR 32280404) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK -1,167,000 and a net result of DKK -1,307,000 compared with DKK -1,130,000 the year before. Equity in the 2014 report amounted to DKK 4,708,000. The solvency ratio was 61.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,167,000
- Profit/Loss
- DKK -1,307,000
- Equity
- DKK 4,708,000
- Total Assets
- DKK 7,629,000
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | -1.2M | -1.3M | 4.7M | 1 |
| 2013 | - | -699K | -1.1M | 6M | 1 |
| 2012 | - | -756K | -1.2M | 5.6M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
Ranger Biotechnologies A/S has published its annual report for 2013. Gross profit came to DKK -699,000, and the net result was DKK -1,130,000.
About Ranger Biotechnologies A/S
Ranger Biotechnologies A/S is a Danish company of the type Aktieselskab based in Odense SØ, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MIRRX THERAPEUTICS A/S and MIRX THERAPEUTICS A/S. The management consists of Hans Thorleif Møller. The board consists of Christina Møller Udesen (chair), Hans Thorleif Møller, Kasper Tvede Larsen and Søren Tvede Larsen. The company is owned by QUERDENKER ApS and Outlate Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -409,444 and a net result of DKK -843,419 compared with DKK -1,138,092 the year before. Equity in the 2025 report amounted to DKK 711,273.